SUBSCRIBE
SUBSCRIBE
News   Drug Development

Myriad Pharmaceuticals, Inc.'s Tablet Formulation of MPC-4326 Reduces Viral Load in HIV-1 Patients

September 14, 2009 | 
1 min read
SALT LAKE CITY, Sept. 14, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the presentation of two abstracts detailing positive data for MPC-4326, its novel maturation inhibitor for the treatment of HIV infection.
Clinical research Phase 2
MORE ON THIS TOPIC
Opportunity of winning. man sees a illuminated trophy door. vector
autoimmune disease
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study
September 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Human kidney made out of lines. Medical Concept. 3D Rendering.
Kidney disease
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
September 23, 2026
 · 
2 min read
 · 
Annalee Armstrong
Microscope icon. Molecule and communication background. Connected lines with dots.
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
September 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Close up shot red darts arrows in the target center on dark blue sky background. Business target or goal success and winner concept.
ALS
Ionis-Otsuka offer ‘groundbreaking’ improvement in function and survival for genetic type of ALS
September 23, 2026
 · 
4 min read
 · 
Heather McKenzie